Initiator Pharma A/S (SE:INIT)
:INIT
Want to see SE:INIT full AI Analyst Report?
INIT Stock Chart & Stats
kr3.04
-kr0.20(-3.17%)
At close: 4:00 PM EST
kr3.04
-kr0.20(-3.17%)
Day’s Range― - ―
52-Week Rangekr2.53 - kr4.17
Previous CloseN/A
Volume47.38K
Average Volume (3M)133.41K
Market Cap
kr180.72M
Enterprise Valuekr129.58M
Total Cash (Recent Filing)kr19.90M
Total Debt (Recent Filing)kr7.56M
Price to Earnings (P/E)―
Beta0.61
Next Earnings
Aug 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.33
Shares Outstanding68,452,890
10 Day Avg. Volume157,519
30 Day Avg. Volume133,406
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)4.31
Price to Sales (P/S)0.00
P/FCF Ratio-7.18
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.31
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Modest LeverageVery low debt reduces refinancing and interest-rate risk for a clinical-stage biotech. Modest leverage preserves strategic optionality to raise capital via equity or partnerships, supporting continued R&D spending without immediate debt-service constraints over the next several quarters.
Focused Pipeline & ModelA targeted small-molecule pipeline in unmet sexual and reproductive health niches creates clear clinical focus and partnership appeal. Specialization supports efficient resource allocation, easier licensing or co-development deals, and durable commercial potential if lead programs prove successful.
Lean Operating FootprintA very small headcount implies a lean corporate structure and likely reliance on CROs and partners, lowering fixed overhead. This operating model can extend cash runway per spend level and make the company more flexible in negotiating collaborations and out-licensing arrangements.
Bears Say
No Revenue, Widening LossesPre-revenue status with materially wider losses is a persistent structural risk: without commercial cash flow the company must rely on external funding to progress trials. Continued losses weaken financial resilience and reduce visibility on sustainable operations beyond near-term milestones.
Persistent Cash BurnSustained negative operating cash flow and FCF indicate ongoing funding needs. Over a multi-quarter horizon this erodes runway, raises the probability of dilutive equity raises or restrictive financing, and can slow program timelines if new capital is delayed or costly.
Eroding Equity And Negative ROEDeclining equity and meaningfully negative ROE reflect value dilution from consecutive losses. This reduces the balance-sheet buffer for development setbacks, increases dependence on external capital, and heightens dilution risk for existing shareholders during future financing rounds.
INIT FAQ
What was Initiator Pharma A/S’s price range in the past 12 months?
Initiator Pharma A/S lowest stock price was kr2.53 and its highest was kr4.17 in the past 12 months.
What is Initiator Pharma A/S’s market cap?
Initiator Pharma A/S’s market cap is kr180.72M.
When is Initiator Pharma A/S’s upcoming earnings report date?
Initiator Pharma A/S’s upcoming earnings report date is Aug 21, 2026 which is in 65 days.
How were Initiator Pharma A/S’s earnings last quarter?
Initiator Pharma A/S released its earnings results on May 08, 2026. The company reported -kr0.242 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.242.
Is Initiator Pharma A/S overvalued?
According to Wall Street analysts Initiator Pharma A/S’s price is currently Overvalued.
Does Initiator Pharma A/S pay dividends?
Initiator Pharma A/S does not currently pay dividends.
What is Initiator Pharma A/S’s EPS estimate?
Initiator Pharma A/S’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Initiator Pharma A/S have?
Initiator Pharma A/S has 68,452,890 shares outstanding.
What happened to Initiator Pharma A/S’s price movement after its last earnings report?
Initiator Pharma A/S reported an EPS of -kr0.242 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.297%.
Which hedge fund is a major shareholder of Initiator Pharma A/S?
Currently, no hedge funds are holding shares in SE:INIT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Initiator Pharma A/S
Initiator Pharma A/S is a clinical-stage life sciences firm dedicated to discovering therapeutic solutions for critical unmet medical needs affecting the central and peripheral nervous systems. Its development pipeline features several clinical-phase compounds: IP2018, a monoamine reuptake inhibitor aimed at psychogenic erectile dysfunction; IPED2015, designed to address organic erectile dysfunction; and IPTN2021, an orphan drug candidate for severe neuropathic pain. Additionally, the company holds early-stage assets, including IPNP2015 for chronic pain management and IPDP2015 for depression. Established in 2016, Initiator Pharma A/S maintains its headquarters in Copenhagen, Denmark.